Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.19
-0.84 (-2.71%)
At close: Aug 26, 2026, 4:00 PM EDT
30.82
+0.63 (2.07%)
After-hours: Aug 26, 2026, 7:58 PM EDT

Beam Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
156.04139.7463.52377.7160.9251.84
Revenue Growth
158.89%120.01%-83.18%520.01%17.51%215916.67%
Gross Profit
-252.63-269.88-304.04-59.67-250.67-180.29
Operating Income
-378.02-383.69-415.57-176.49-338.48-237.51
Net Income
-86.52-79.99-376.74-132.53-289.09-370.64
Earnings Per Share
-0.84-0.81-4.58-1.72-4.13-5.77
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,1531,245850.741,1901,078965.65
Total Debt
247.36154.12161.43172.69180.86147.64
Net Cash (Debt)
905.571,091689.321,017897.28818
Net Cash Growth
-9.04%58.29%-32.23%13.36%9.69%325.98%
Net Cash Per Share
8.7711.038.3713.1812.8212.74

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-359.38-345.1-347.25-149.222.53-66.27
Capital Expenditures
-13.39-14.95-8.95-33.73-48.95-46.81
Free Cash Flow
-372.77-360.05-356.19-182.93-26.42-113.08
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-161.91%-193.12%--15.80%--
Operating Margin
-242.27%-274.57%-654.25%-46.73%-555.61%-458.13%
Pretax Margin
-55.45%-57.24%-593.06%-34.73%-468.94%-714.91%
Profit Margin
-55.45%-57.24%-593.13%-35.09%-474.54%-714.91%
FCF Margin
-238.90%-257.65%-560.77%-48.43%-43.38%-218.11%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
19.3319.5831.085.7244.18102.75